SLC35C1 and congenital disorder of glycosylation: L-Fucose administration to SLC35C1-CDG (congenital disorders of glycosylation) patients via their daily food intake reduces immunological and other clinical symptoms, potentially by allowing the utilization of the external source of sugar through a poorly characterized salvage pathway21.